<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Catecholaminergic polymorphic <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e>) is an inherited <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> syndrome characterized by VT induced by adrenergic stress in the absence of structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> and high incidence of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis is made based on reproducible ventricular tachyarrhythmias including bidirectional VT and polymorphic VT during exercise testings </plain></SENT>
<SENT sid="2" pm="."><plain>Two causative genes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> have been identified: RYR2, encoding the cardiac <z:chebi fb="0" ids="8925">ryanodine</z:chebi> receptor (RyR2) Ca(2+) release channel, and CASQ2, encoding cardiac calsequestrin </plain></SENT>
<SENT sid="3" pm="."><plain>A mutation in RYR2 or CASQ2 is identified in approximately 60% of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Mutations in these two genes destabilize the RyR2 Ca(2+) release channel complex in sarcoplasmic reticulum and result in spontaneous Ca(2+) release through RyR2 channels leading to delayed after depolarization, triggered activity, and bidirectional/polymorphic VT </plain></SENT>
<SENT sid="5" pm="."><plain>Implantable cardioverter defibrillators (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICDs</z:e>) are recommended for prevention of <z:hpo ids='HP_0001699'>sudden death</z:hpo> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e>.1 </plain></SENT>
<SENT sid="6" pm="."><plain>A.E </plain></SENT>
<SENT sid="7" pm="."><plain>Epstein, J.P </plain></SENT>
<SENT sid="8" pm="."><plain>DiMarco, K.A </plain></SENT>
<SENT sid="9" pm="."><plain>Ellenbogen, et al., ACC/<z:chebi fb="30" ids="27777">AHA</z:chebi>/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/<z:chebi fb="30" ids="27777">AHA</z:chebi>/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons </plain></SENT>
<SENT sid="10" pm="."><plain>Circulation </plain></SENT>
<SENT sid="11" pm="."><plain>2008;117:e350 However, painful shocks can trigger further adrenergic stress and <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, and <z:hpo ids='HP_0011420'>deaths</z:hpo> have occurred despite appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> shocks </plain></SENT>
<SENT sid="12" pm="."><plain>Treatment with β-<z:chebi fb="0" ids="37887">adrenergic blockers</z:chebi> reduces <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> burden and mortality, but is not completely effective </plain></SENT>
<SENT sid="13" pm="."><plain>The beneficial effects of Ca(2+) channel blocker <z:chebi fb="1" ids="9948">verapamil</z:chebi> in combination with β-blocker have been reported, but the role of <z:chebi fb="1" ids="9948">verapamil</z:chebi> has not been well assessed </plain></SENT>
<SENT sid="14" pm="."><plain>Because Ca(2+) leakage through <z:chebi fb="0" ids="8925">ryanodine</z:chebi> channel is a common mechanism of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e>, <z:chebi fb="0" ids="8925">ryanodine</z:chebi> channel block may have a therapeutic effect </plain></SENT>
<SENT sid="15" pm="."><plain>We discovered that flecainide directly inhibits RyR2 channels and prevent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CPVT</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>Left cardiac sympathetic denervation may be an effective alternative treatment in combination with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>, especially for patients whose <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> are not controlled by drug therapies </plain></SENT>
</text></document>